MedPath

Randomized controlled trial to evaluate the prediction of the effectiveness for HLA-oriented therapy in gastric and colorectal cancer.

Not Applicable
Conditions
Gastric cancer Colorectal cancer
Registration Number
JPRN-UMIN000037475
Lead Sponsor
Japan cancer treatment and behavior study group(JCTB)
Brief Summary

We failed to confirm that HLA B40 and B51 antigens significantly associated with response to PSK therapy.

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
432
Inclusion Criteria

Not provided

Exclusion Criteria

1. Double cancer. 2. Prior cytotoxic or radiation therapy. 3. Abnormal bone marrow, hepatic and renal function 4. Severe cardiac, hepatic and lung failure, and an attending doctor was considered unsuitable.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath